The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
The STRIDE Weight Loss and Lifestyle Intervention for Individuals Taking Antipsychotic Medications: A Randomized Trial
Open accessAbstract
OBJECTIVES: The STRIDE study assessed whether a lifestyle intervention, tailored for individuals with serious mental illnesses, reduced weight and diabetes risk. The authors hypothesized that the STRIDE intervention would be more effective than usual care in reducing weight and improving glucose metabolism. METHOD: The study design was a multisite, parallel two-arm randomized controlled trial in community settings and an integrated health plan. Participants who met inclusion criteria were ≥18 years old, were taking antipsychotic agents for ≥30 days, and had a body mass index ≥27. Exclusions were significant cognitive impairment, pregnancy/breastfeeding, recent psychiatric hospitalization, bariatric surgery, cancer, heart attack, or stroke. The intervention emphasized moderate caloric reduction, the DASH (Dietary Approaches to Stop Hypertension) diet, and physical activity. Blinded staff collected data at baseline, 6 months, and 12 months. RESULTS: Participants (men, N=56; women, N=144; mean age=47.2 years [SD=10.6]) were randomly assigned to usual care (N=96) or a 6-month weekly group intervention plus six monthly maintenance sessions (N=104). A total of 181 participants (90.5%) completed 6-month assessments, and 170 (85%) completed 12-month assessments, without differential attrition. Participants attended 14.5 of 24 sessions over 6 months. Intent-to-treat analyses revealed that intervention participants lost 4.4 kg more than control participants from baseline to 6 months (95% CI=-6.96 kg to -1.78 kg) and 2.6 kg more than control participants from baseline to 12 months (95% CI=-5.14 kg to -0.07 kg). At 12 months, fasting glucose levels in the control group had increased from 106.0 mg/dL to 109.5 mg/dL and decreased in the intervention group from 106.3 mg/dL to 100.4 mg/dL. No serious adverse events were study-related; medical hospitalizations were reduced in the intervention group (6.7%) compared with the control group (18.8%). CONCLUSIONS: Individuals taking antipsychotic medications can lose weight and improve fasting glucose levels. Increasing reach of the intervention is an important future step.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“Moreover, STRIDE study subjects had average baseline fasting glucose levels of 109mg/dl (35), and were therefore similar to subjects enrolled in diabetes prevention trials with multi-year lifestyle interventions (36, 37).”
BackgroundTuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“Moreover, STRIDE study subjects had average baseline fasting glucose levels of 109mg/dl (35), and were therefore similar to subjects enrolled in diabetes prevention trials with multi-year lifestyle interventions (36, 37).”
BackgroundDiagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Lindström, J., Ilanne-Parikka, P., Peltonen, M., Aunola, S., Eriksson, J. G., Hemiö, K., Hämäläinen, H., Härkönen, P., Keinänen-Kiukaanniemi, S., Laakso, M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69701-8 · Cited by 1,799
Li, G., Zhang, P., Wang, J., Gregg, E. W., Yang, W., Gong, Q., Li, H., Li, H., Jiang, Y., An, Y., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60766-7 · Cited by 1,600
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · cited 1×
“Our results support recent findings (14) suggesting that behavioral lifestyle-change programs can help individuals with SMI to lose weight, and extend these findings by showing that lifestyle interventions can produce changes in fasting glucose levels among individuals taking antipsychotic medications—drugs known to d…”
ResultObarzanek, E., Sacks, F. M., Vollmer, W. M., Bray, G. A., Miller, E. R., Lin, P.-H., Karanja, N. M., Most-Windhauser, M. M., Moore, T. J., Swain, J. F., et al. (2001) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/74.1.80 · Cited by 598
Elmer, P. J., Obarzanek, E., Vollmer, W. M., Simons-Morton, D., Stevens, V. J., Young, D. R., Lin, P.-H., Champagne, C., Harsha, D. W., Svetkey, L. P., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-7-200604040-00007 · Cited by 596
Self-citationGoff, D. C., Sullivan, L. M., McEvoy, J. P., Meyer, J. M., Nasrallah, H. A., Daumit, G. L., Lamberti, S., D'Agostino, R. B., Stroup, T. S., Davis, S., et al. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.08.010 · Cited by 528
A Behavioral Weight-Loss Intervention in Persons with Serious Mental Illness
Daumit, G. L., Dickerson, F. B., Wang, N.-Y., Dalcin, A., Jerome, G. J., Anderson, C. A. M., Young, D. R., Frick, K. D., Yu, A., Gennusa, J. V., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214530 · Cited by 523 · cited 2×
“Our results parallel ACHIEVE study results (32) and are consistent with those of other randomized controlled trials in showing positive results of weight-loss interventions in this population (16).”
BackgroundResultCook, B. L., Wayne, G. F., Kafali, E. N., Liu, Z., Shu, C., & Flores, M. (2014) · JAMA · doi:10.1001/jama.2013.284985 · Cited by 519 · cited 1×
“Additional contributing factors include metabolic consequences of antipsychotic medications (6, 7), limited access to medical care (8), poor nutrition (9), hyperlipidemia (10), sedentary lifestyles (5), smoking (11), and substance abuse (12).”
BackgroundThe Effect of the PREMIER Interventions on Insulin Sensitivity
Ard, J. D., Grambow, S. C., Liu, D., Slentz, C. A., Kraus, W. E., & Svetkey, L. P. (2004) · Diabetes Care · doi:10.2337/diacare.27.2.340 · Cited by 106 · cited 1×
“PREMIER successfully reduces weight and blood pressure (25); DASH diet can increase HDL cholesterol, lower triglycerides, reduce fasting blood glucose levels, and improve insulin resistance (23, 26).”
BackgroundFunk, K. L., Elmer, P. J., Stevens, V. J., Harsha, D. W., Craddick, S. R., Lin, P.-H., Young, D. R., Champagne, C. M., Brantley, P. J., McCarron, P. B., et al. (2008) · Health Promotion Practice · doi:10.1177/1524839906289035 · Cited by 74
Self-citation
Cited by
Liu, N. H., Daumit, G. L., Dua, T., Aquila, R., Charlson, F., Cuijpers, P., Druss, B., Dudek, K., Freeman, M., Fujii, C., et al. (2017) · World Psychiatry · doi:10.1002/wps.20384 · Cited by 865
Management of common adverse effects of antipsychotic medications
Stroup, T. S., & Gray, N. (2018) · World Psychiatry · doi:10.1002/wps.20567 · Cited by 572
Filippou, C. D., Tsioufis, C. P., Thomopoulos, C. G., Mihas, C. C., Dimitriadis, K. S., Sotiropoulou, L. I., Chrysochoou, C. A., Nihoyannopoulos, P. I., & Tousoulis, D. M. (2020) · Advances in Nutrition · doi:10.1093/advances/nmaa041 · Cited by 539
Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645254 · Cited by 292
Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management
Manu, P., Dima, L., Shulman, M., Vancampfort, D., De Hert, M., & Correll, C. U. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12445 · Cited by 285
Metadata
- Authors
- Green, C. A., Yarborough, B. J. H., Leo, M. C., Yarborough, M. T., Stumbo, S. P., Janoff, S. L., Perrin, N. A., Nichols, G. A., & Stevens, V. J.
- Venue
- American Journal of Psychiatry
- Published
- 2015-01-01
- Volume
- 172
- Issue
- 1
- Pages
- 71-81
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2111224842
- Cited by
- 210
- References
- 15
- FWCI
- 19.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.